成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Cell Cycle/DNA Damage Cytoskeleton Apoptosis Metabolic Enzyme/Protease
  2. Microtubule/Tubulin Apoptosis Endogenous Metabolite
  3. Docetaxel

Docetaxel  (Synonyms: 多西他賽; RP-56976)

目錄號: HY-B0011 純度: 99.91%
COA 產(chǎn)品使用指南

Docetaxel (RP-56976) 是一種微管解聚 (microtubule?depolymerization) 抑制劑,其 IC50 值為 0.2 μM。Docetaxel 是紫杉醇的半合成類似物,能減弱 bcl-2bcl-xL 基因表達的影響。Docetaxel 阻滯 G2/M 細胞周期,導致細胞凋亡 (apoptosis)。Docetaxel 具有抗腫瘤活性。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務

Docetaxel Chemical Structure

Docetaxel Chemical Structure

CAS No. : 114977-28-5

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(單位)同一產(chǎn)品試用裝僅限申領一次,同一機構(單位)一年內

     可免費申領三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥737
In-stock
25 mg ¥670
In-stock
50 mg ¥990
In-stock
100 mg ¥1750
In-stock
200 mg ¥2800
In-stock
500 mg ¥4900
In-stock
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Docetaxel:

MCE 顧客使用本產(chǎn)品發(fā)表的 101 篇科研文獻

WB

    Docetaxel purchased from MCE. Usage Cited in: Arch Biochem Biophys. 2023 Feb 21;109551.  [Abstract]

    Docetaxel (30 nM) exhibits anti-tumor activity in parental (DU145 and PC-3) and docetaxel-resistant (DU145/DTX50 and PC-3/DTX30) cell lines by down-regulating KIF14 expression.

    Docetaxel purchased from MCE. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902.  [Abstract]

    Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with XRP6258 (Cab). Graphs represent the densimetric semi-quantification of western blot images.
    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Docetaxel (RP-56976) is a microtubule?depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of?bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].

    IC50 & Target

    Microtubule[1]

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A2780 IC50
    11.2 nM
    Compound: 1b
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 29359935]
    A549 IC50
    19.5 nM
    Compound: Docetaxel
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 34058663]
    A549 IC50
    3.41 μM
    Compound: DTX
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    [PMID: 26791014]
    A549 IC50
    734 nM
    Compound: Docetaxel
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay
    [PMID: 30036834]
    A549 IC50
    9.8 nM
    Compound: Docetaxel
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    [PMID: 30036834]
    A549/TR IC50
    836.2 nM
    Compound: Docetaxel
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 34058663]
    Calu-1 IC50
    0.4 nM
    Compound: Docetaxel
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay
    [PMID: 30629433]
    CAPAN-1 IC50
    0.0088 μM
    Compound: Docetaxel
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    [PMID: 33248847]
    CAPAN-1 IC50
    0.025 μM
    Compound: Docetaxel
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    [PMID: 32832030]
    CCD-18Co IC50
    116.54 μM
    Compound: DTX
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32203786]
    CWR22R CC50
    1 nM
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34717125]
    CWR22R CC50
    3.3 nM
    Compound: Docetaxel
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
    [PMID: 34797052]
    CWR22R GI50
    6 ng/mL
    Compound: Dxtl
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
    [PMID: 31767266]
    DU-145 IC50
    0.0012 μM
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    [PMID: 33753258]
    DU-145 IC50
    0.0012 μM
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay
    [PMID: 29784275]
    DU-145 IC50
    0.01 μM
    Compound: Docetaxel
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    [PMID: 29120172]
    DU-145 IC50
    0.026 μM
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 27077446]
    DU-145 IC50
    0.1 nM
    Compound: Docetaxel
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
    [PMID: 29406710]
    DU-145 CC50
    0.81 μM
    Compound: Docetaxel
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    [PMID: 29120172]
    DU-145 IC50
    4.95 nM
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31945665]
    DU-145 IC50
    43.25 nM
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31945665]
    DU-145 IC50
    5 μg/mL
    Compound: Docetaxel
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay
    [PMID: 34000484]
    DU-145 IC50
    8.58 μM
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    [PMID: 33753258]
    HCT-116 IC50
    0.0017 μM
    Compound: Docetaxel
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    [PMID: 33248847]
    HCT-116 IC50
    0.007 μM
    Compound: Docetaxel
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    [PMID: 32832030]
    HCT-116 IC50
    129.8 nM
    Compound: Docetaxel
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 28972762]
    HCT-116 IC50
    3.5 nM
    Compound: DTX
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32203786]
    HCT-116 IC50
    4 nM
    Compound: Docetaxel
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 33221063]
    HEK293 IC50
    0.11 μM
    Compound: Docetaxel
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    [PMID: 29120172]
    HEK293 CC50
    1.6 μM
    Compound: Docetaxel
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    [PMID: 29120172]
    HEK293 IC50
    19.7 μM
    Compound: DTX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32203786]
    HeLa IC50
    0.061 μM
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 27077446]
    HeLa IC50
    0.07 μM
    Compound: Docetaxel
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    [PMID: 29120172]
    HeLa CC50
    0.09 μM
    Compound: Docetaxel
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    [PMID: 29120172]
    HeLa IC50
    0.3 nM
    Compound: Docetaxel
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 30629433]
    HeLa IC50
    0.68 μM
    Compound: Docetaxel
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    [PMID: 36126331]
    HeLa IC50
    13 μM
    Compound: Docetaxel
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
    [PMID: 27894589]
    HeLa IC50
    3.23 μM
    Compound: DTX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    [PMID: 26791014]
    HeLa IC50
    3.5 nM
    Compound: 1b
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 29359935]
    HeLa IC50
    4 μM
    Compound: Docetaxel
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 27894589]
    HEp-2 CC50
    0.06 μM
    Compound: Docetaxel
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    [PMID: 29120172]
    HEp-2 IC50
    0.06 μM
    Compound: Docetaxel
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    [PMID: 29120172]
    HepG2 IC50
    2.86 μM
    Compound: DTX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    [PMID: 26791014]
    HepG2 IC50
    8.3 μM
    Compound: Docetaxel
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 27617953]
    HEY IC50
    0.86 μM
    Compound: Taxotere
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
    [PMID: 29517223]
    HL-60 IC50
    0.0072 μM
    Compound: Docetaxel
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    [PMID: 33248847]
    HL-60 IC50
    0.05 μM
    Compound: Docetaxel
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    [PMID: 32832030]
    K562 IC50
    0.009 μM
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    [PMID: 32832030]
    K562 IC50
    0.0152 μM
    Compound: Docetaxel
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    [PMID: 33248847]
    K562 IC50
    0.039 μM
    Compound: Docetaxel
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 27077446]
    KB IC50
    0.05 μM
    Compound: Docetaxel
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    [PMID: 29120172]
    KB GI50
    0.13 nM
    Compound: Docetaxel
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    Growth inhibition of human KB cells after 72 hrs by MTS assay
    [PMID: 26778612]
    KB CC50
    0.18 μM
    Compound: Docetaxel
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    [PMID: 29120172]
    KB IC50
    17.5 nM
    Compound: Docetaxel
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 34058663]
    KB IC50
    38 nM
    Compound: Docetaxel
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    [PMID: 30407813]
    KB IC50
    7.3 nM
    Compound: Docetaxel
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    [PMID: 30036834]
    L132 IC50
    1.68 μM
    Compound: DTX
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    [PMID: 26791014]
    LN-229 IC50
    0.002 μM
    Compound: Docetaxel
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    [PMID: 32832030]
    LNCaP IC50
    0.0002 μM
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    [PMID: 33753258]
    LNCaP IC50
    0.0002 μM
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay
    [PMID: 29784275]
    MCF7 CC50
    0.01 μM
    Compound: Docetaxel
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    [PMID: 29120172]
    MCF7 IC50
    0.01 μM
    Compound: Docetaxel
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    [PMID: 29120172]
    MCF7 IC50
    0.022 μM
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 27077446]
    MCF7 IC50
    0.5 nM
    Compound: Docetaxel
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 30629433]
    MCF7 IC50
    0.8 μM
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    [PMID: 27240278]
    MCF7 IC50
    1.7 nM
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    [PMID: 30036834]
    MCF7 IC50
    10.3 nM
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 30407813]
    MCF7 IC50
    3.6 μM
    Compound: DTX
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control
    [PMID: 26791014]
    MDA-MB-231 IC50
    0.01 μM
    Compound: Docetaxel
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    [PMID: 33139111]
    MDA-MB-231 IC50
    0.032 μM
    Compound: Docetaxel
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 27077446]
    MDA-MB-231 IC50
    0.07 μM
    Compound: Docetaxel
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    [PMID: 29120172]
    MDA-MB-231 CC50
    0.19 μM
    Compound: Docetaxel
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    [PMID: 29120172]
    MM1.S IC50
    0.0118 μM
    Compound: Docetaxel
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    [PMID: 33248847]
    MV4-11 GI50
    0.0005 μM
    Compound: Taxotere
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    [PMID: 30802730]
    NCI/ADR-RES IC50
    1530.5 nM
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    [PMID: 30036834]
    NCI/ADR-RES IC50
    21.2 μM
    Compound: Docetaxel
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    [PMID: 27240278]
    NCI-H460 IC50
    0.0024 μM
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    [PMID: 33248847]
    NCI-H460 IC50
    0.004 μM
    Compound: Docetaxel
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    [PMID: 32832030]
    PC-3 IC50
    0.0006 μM
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    [PMID: 36126331]
    PC-3 IC50
    0.0019 μM
    Compound: Docetaxel
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    [PMID: 33753258]
    PC-3 IC50
    0.0019 μM
    Compound: Docetaxel
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay
    [PMID: 29784275]
    PC-3 IC50
    0.013 μM
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 27077446]
    PC-3 IC50
    0.5 nM
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    [PMID: 29406710]
    PC-3 IC50
    0.6 nM
    Compound: Docetaxel
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    [PMID: 30629433]
    PC-3 CC50
    1 nM
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34717125]
    PC-3 IC50
    2.34 μM
    Compound: Docetaxel
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay
    [PMID: 33753258]
    PC-3 CC50
    6.7 nM
    Compound: Docetaxel
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
    [PMID: 34797052]
    PC-3 IC50
    8 nM
    Compound: Docetaxel
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay
    [PMID: 28462831]
    PC-3 GI50
    9 ng/mL
    Compound: Dxtl
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
    [PMID: 31767266]
    RWPE-1 IC50
    1.73 μM
    Compound: Docetaxel
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 27077446]
    SH-SY5Y IC50
    0.0018 μM
    Compound: Docetaxel
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
    [PMID: 36126331]
    SiHa IC50
    0.09 μM
    Compound: Docetaxel
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    [PMID: 29120172]
    SiHa CC50
    0.22 μM
    Compound: Docetaxel
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    [PMID: 29120172]
    SK-MEL19 GI50
    0.002 μM
    Compound: Taxotere
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    [PMID: 30802730]
    SK-OV-3 IC50
    0.75 nM
    Compound: Taxotere
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
    [PMID: 29517223]
    SW-620 IC50
    0.02 μM
    Compound: DTX
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32203786]
    SW-620 IC50
    4.7 nM
    Compound: Docetaxel
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 33221063]
    T84 IC50
    2.7 nM
    Compound: Docetaxel
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 33221063]
    TERT-RPE1 IC50
    0.0553 μM
    Compound: Docetaxel
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    [PMID: 33248847]
    U-251 IC50
    0.7 nM
    Compound: Docetaxel
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay
    [PMID: 30629433]
    Vero IC50
    0.13 μM
    Compound: Docetaxel
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    [PMID: 29120172]
    Vero CC50
    1.3 μM
    Compound: Docetaxel
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    [PMID: 29120172]
    Z-138 IC50
    0.004 μM
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    [PMID: 32832030]
    Z-138 IC50
    0.0142 μM
    Compound: Docetaxel
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    [PMID: 33248847]
    體外研究
    (In Vitro)

    Docetaxel (RP-56976) 和葡磷酰胺 (GLU) 的單一和聯(lián)合處理以劑量依賴的方式影響細胞活力。GLU在PC-3和LNCaP細胞中的IC50分別為70±4 μM和86.8±8 μM。同時,在 PC-3 和 LNCaP 細胞中,單用 Docetaxel 的 IC50 分別為 3.08±0.4 nM 和 1.46±0.2 nM
    GLU與 Docetaxel 聯(lián)合處理可協(xié)同細胞毒性,PC-3 和 LNCaP 細胞的 IC50 值分別降低至2.7±0.1 nM和0.75±0.3 nM[1]。
    Docetaxel 對 NCI-H460 的 IC50 在24小時為116 nM,在72小時為30 nM。根據(jù) DTP 數(shù)據(jù)搜索中報告的數(shù)據(jù),NCI-60 細胞板對 Docetaxel 的平均 IC50 為 14-34 nM[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內研究
    (In Vivo)

    在雌性小鼠中,光照后 14 小時 (HALO) 組中 Docetaxel (RP-56976) 誘導的腸細胞凋亡明顯大于 2-HALO 組。Bax 表達在 2-HALO 組中被 Docetaxel 顯著升高,但在 14-HALO 組中沒有。另一方面,Docetaxel 在 14-HALO 組中顯著升高了裂解的 Caspase-3 表達,但在 2-HALO 組中沒有。Wee1 和磷酸化 CKD1 的表達在 Docetaxel 給藥后在 14 HALO 時顯著升高,但在 2 HALO 時沒有。此外,Docetaxel 顯著降低 14-HALO 組中的存活蛋白表達,但不降低 2-HALO 組中的存活蛋白表達。Docetaxel 處理14-HALO組 survivin 表達水平明顯低于藥物處理2-HALO組[3]。
    胡椒堿 (PIP) 通過靜脈給藥以 3.5 mg/kg 推注并以 35 mg/kg 和 3.5 mg/kg 口服給藥,而 Docetaxel (DOX) 以 7 mg/kg 靜脈內給藥至 Sprague-Daley 大鼠。在 Sprague-Dawley 大鼠中通過口服給藥 35 mg/kg 的 PIP 和通過靜脈推注給藥 7 mg/kg 的 Docetaxel 共同給藥。PIP 和 Docetaxel 的聯(lián)合使用導致它們體內暴露的協(xié)同增加[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    807.88

    Formula

    C43H53NO14

    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    多西他賽;多西紫杉醇

    結構分類
    初始來源
    運輸條件

    Room temperature in continental US; may vary elsewhere.

    儲存方式

    4°C, protect from light

    *In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

    溶解性數(shù)據(jù)
    細胞實驗: 

    DMSO 中的溶解度 : 100 mg/mL (123.78 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響,請使用新開封的 DMSO)

    Ethanol 中的溶解度 : 50 mg/mL (61.89 mM; 超聲助溶)

    配制儲備液
    濃度 溶劑體積 質量 1 mg 5 mg 10 mg
    1 mM 1.2378 mL 6.1890 mL 12.3781 mL
    5 mM 0.2476 mL 1.2378 mL 2.4756 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C儲存時,請在1年內使用, -20°C儲存時,請在6個月內使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗:

    請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
    ——為保證實驗結果的可靠性,澄清的儲備液可以根據(jù)儲存條件,適當保存;體內實驗的工作液,建議您現(xiàn)用現(xiàn)配,當天使用;
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑: 10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (6.19 mM); 澄清溶液

      此方案可獲得 ≥ 5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 50.0 mg/mL 的澄清 EtOH 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑: 10% EtOH    90% Corn Oil

      Solubility: ≥ 5 mg/mL (6.19 mM); 澄清溶液

      此方案可獲得 ≥ 5 mg/mL(飽和度未知)的澄清溶液,此方案實驗周期在半個月以上的動物實驗酌情使用。

      1 mL 工作液為例,取 100 μL 50.0 mg/mL 的澄清 EtOH 儲備液加到 900 μL 玉米油中,混合均勻。

    動物溶解方案計算器
    請輸入動物實驗的基本信息:

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    由于實驗過程有損耗,建議您多配一只動物的量
    請輸入您的動物體內配方組成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括:DMSO ,均可在 MCE 網(wǎng)站選購。 ,Tween 80,均可在 MCE 網(wǎng)站選購。
    計算結果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。

    *In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術支持聯(lián)系。
    動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL  μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水
    連續(xù)給藥周期超過半月以上,請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.91%

    參考文獻
    Cell Assay
    [1]

    Single-drug concentration-response curves are assessed. Seeding is done at a density of 2,000 cells/well for PC-3 and LNCaP, in 96-well plates. Cells are treated with each single drug and their combination for 72 h at different drug concentrations. Docetaxel is used at concentrations of 0.1-1,000 nM. GLU is used at concentrations of 0.1-300 μm. Cytotoxicity is assessed at the end of drug exposure using SRB assay. Following 72 h exposure the cells are fixed with 10% trichloroacetic acid (150 μL) for 1 h at 4°C. Then, cells are stained for 10 min at room temperature with 0.4% SRB dissolved in 1% acetic acid. The plates are then air dried for 24 h and the dye is made soluble with 150 μL Tris (10 mM, PH 7.4) for 5 min on a shaker at 1,600 rpm. Absorbance is then measured at 545 nM using microplate reader. Results are expressed as the relative percentage of absorbance compared to control[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3][4]

    Mice[3]
    Five-week-old male Balb/c mice are used. Docetaxel (0, 10, 20, 30, 40, 60, and 80 mg/kg per week) is given once a week for 3 weeks for mice. Because more than 30 mg/kg per week of Docetaxel causes body weight loss in mice, 20 mg/kg per week of Docetaxel is judged to be the maximum nontoxic dose. Docetaxel (20 mg/kg per week) is given to mice once a week for 3 weeks at one of the following different points (2, 10, 14, or 22 HALO). Seventy-two hours after the final dosing of the agent, the intestinal mucosa of the small intestine (proximal 8 cm) is removed, fixed in 20 N Mildform solution (containing 8% formaldehyde in a buffered solution), and embedded in paraffin blocks, and sections of 5 μm are put on glass slides. Apoptosis is detected using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, using the Apop Tag Peroxidase In Situ Apoptosis Detection Kit.
    Rats[4]
    Male Sprague-Dawley rats with body weight between 230-250 g and age between 6-7 weeks are used. About 25 SD rats are divided into five groups receiving Docetaxel (7 mg/kg, i.v.), PIP (35 mg/kg, p.o.) and their combined administration (DOX+PIP) as well as PIP (3.5 mg/kg, p.o.) and PIP (3.5 mg/kg, i.v.). A day before the drug administrations, the rats are anesthetized. Right jugular vein is cannulated with a polyethylene tubing (0.5 mm ID, 1 mm) for blood collection.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C儲存時,請在1年內使用, -20°C儲存時,請在6個月內使用。

    可選溶劑 濃度 溶劑體積 質量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 1.2378 mL 6.1890 mL 12.3781 mL 30.9452 mL
    5 mM 0.2476 mL 1.2378 mL 2.4756 mL 6.1890 mL
    10 mM 0.1238 mL 0.6189 mL 1.2378 mL 3.0945 mL
    15 mM 0.0825 mL 0.4126 mL 0.8252 mL 2.0630 mL
    20 mM 0.0619 mL 0.3095 mL 0.6189 mL 1.5473 mL
    25 mM 0.0495 mL 0.2476 mL 0.4951 mL 1.2378 mL
    30 mM 0.0413 mL 0.2063 mL 0.4126 mL 1.0315 mL
    40 mM 0.0309 mL 0.1547 mL 0.3095 mL 0.7736 mL
    50 mM 0.0248 mL 0.1238 mL 0.2476 mL 0.6189 mL
    60 mM 0.0206 mL 0.1032 mL 0.2063 mL 0.5158 mL
    DMSO 80 mM 0.0155 mL 0.0774 mL 0.1547 mL 0.3868 mL
    100 mM 0.0124 mL 0.0619 mL 0.1238 mL 0.3095 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱:

     

    * 需求量:

    * 客戶姓名:

     

    * Email:

    * 電話:

     

    * 公司或機構名稱:

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱:
    Docetaxel
    目錄號:
    HY-B0011
    需求量: